1. Key Initiatives Victorian Biotechnology Strategy 2004-2007
Aim to be in top 5 biotech cities by 2010
Over $500m committed to biotechnology initiatives
Australian Synchrotron
Kangaroo Genome Sequencing Project
Australian Stem Cell Centre
Victorian Partnership for Advanced Computing
Centre for Pre-Clinical Drug Candidate Optimisation
Nucleus Network
National Neurosciences Facility
Nanotechnology Victoria
Bio21 Institute
Graham Clarke Institute (formerly Bionic Ear Institute)
RMIT Drug Discovery Technologies (RDDT)
VESKI
Bringing Australian expatriate scientists back to Australia

2. Drug Development Capabilities
Centre for Drug
Candidate Optimisation
STC -
GxP Scale-Up MFG
R & D
Pre Clinical
Phase I
Phase II
Phase III
Biopharmaceutical
Formulation and
Finishing Sciences
Centre
AMREP

3. Facts & Figures Over 100 core biotech companies in Melbourne
43 stock market listed companies : Market cap >$16billion
6,100 people employed by Vic biotech companies, 30% emerging biotech companies, 70% established pharma
$280m raised in last 12 months by Victorian Biotechs
In excess of 500 clinical trials conducted across Melbourne institutions annually
More than 20 specialist Medical Research institutes
Home of discoveries such as Colony Stimulating Factors – (GM-CSF), Neuraminidase inhibitors – (Relenza)

4. Contacts Nucleus Network www.nucleusnetwork.com.au
Andrew Giddy
Lisa Nelson
Maria Chiam
Maria is located in San Francisco PH:
Invest Victoria
David Brown
BioMelbourne Network
Tim Murphy
Biotechnology Victoria
Amanda Caples